Polyrizon PLRZ 深 滬
等待開盤 09-24 09:30:00 美东时间
11.16
+0.500
+4.69%
華盛通- 最 高11.99
- 今 開10.62
- 成交量 4.01万股
- 最 低 10.0906
- 昨 收 10.66
- 總市值 2680.71万
- 52周最高 18.20
- 市盈率 靜 --
- 換手率 1.67%
- 52周最低 2.88
- 委 比 -80.95%
- 總股本 240.21万
- 歷史最高 7200.00
- 量 比 0.89
- 振 幅 17.82%
- 歷史最低 4.80
- 每 手 1
- 風險率 3.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Polyrizon Enrolls First Patient In U.S. NASARIX Allergy Blocker Trial, Entering Clinical Stage
First patient marks Polyrizon’s transition into a clinical-stage company. The U.S clinical study is designed to evaluate the efficacy, safety and tolerability of the NASARIX (PL-14) Allergy Blocker in patients with seasonal allergic rhinitis Raanana, Israel, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Polyri...
09-22 20:34
Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement
Polyrizon Ltd. completed a registered direct offering and concurrent private placement, raising approximately $4.0 million. The transactions involved the issuance of 333,333 Units, including Ordinary Shares, Pre-Funded Warrants, and Common Warrants. Aegis Capital Corp. acted as the exclusive placement agent, while Meitar | Law Offices and Kaufman & Canoles, P.C. provided legal counsel. The funds will be used for general corporate purposes and wor...
09-04 15:58
Polyrizon prices $4M registered direct offering
Polyrizon (PLRZ) announced on Thursday it agreed to raise approximately $4M through a registered direct offering and concurrent private placement with a single institutional investor. The transactions...
09-03 21:13
Polyrizon Completes Contracting With Fourth, Fifth Clinical Facilities Participating In Its Clinical Trial Of NASARIX Allergy Blocker
Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced that it has completed contracting with the fourth and fifth clinical sites participating in its clinical study of NASAR...
08-20 21:31
Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment
Polyrizon Ltd. has completed contracting with all five U.S. clinical sites for its NASARIX™ Allergy Blocker study, aiming to enroll 120 patients with seasonal allergic rhinitis. The first-in-human study is a prospective, multicenter, randomized, single-blind trial assessing efficacy, safety, and tolerability. Primary endpoints focus on mean daily reflective Total Nasal Symptom Score (rTNSS) over 14 days, while secondary measures include instantan...
08-20 13:30
Polyrizon Receives Central IRB Approval To Begin First Human Clinical Trial For NASARIX, Nasal Spray Designed To Block Airborne Allergens
Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, announced it has received central IRB approval to begin its first human clinical trial for NASARIX™, the Company’s innovative nasal spr...
06-29 20:45
Polyrizon receives U.S. patent publication notice for nasal drug delivery platform
Polyrizon (PLRZ) on Wednesday said it received notice of publication of a U.S. patent application covering its Trap & Target mucoadhesive polymer technology for nasal drug delivery. The patent applica...
06-17 20:53
Polyrizon Launches Human Study With Top European Medical Center To Validate NASARIX Allergy Blocker's Nasal Residence Time
New performance and characterization study in collaboration with leading European medical center marks a critical milestone in the validation of the NASARIX™ allergy blocker's protective barrier function Raanana, Israel, June 15, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" o...
06-15 20:10
Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial
Polyrizon Ltd. has signed agreements with two additional U.S. clinical sites, bringing the total to three major contracted sites for its upcoming NASARIX™ (PL-14) clinical study. These sites are expected to contribute the highest rates of patient enrollment for evaluating the safety, tolerability, and efficacy of the NASARIX™ Allergy Blocker in patients with seasonal allergic rhinitis. The company believes this progress positions it strongly for ...
06-08 13:25
